Slide 1: Transforming the Future of Chronic Kidney Disease Treatment
Transforming the Future of Chronic Kidney Disease Treatment Corporate Presentation May 2026 Preserving Kidney Function in Patients at High Risk of Kidney Failure Exhibit 99.2
Slide 2: Forward-looking statements
This presentation includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. ProKidney’s actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these fo
Slide 3: Advanced CKD Patients Want More Time
Advanced CKD Patients Want More Time More time before dialysis More time for life’s moments More time and flexibility with the people who matter most Time for Hope
Slide 4: Rilparencel: Buying Meaningful Time
Rilparencel: Buying Meaningful Time NOVEL autologous cell therapy made from a patient’s own kidney cells CLINICAL DATA shows kidney function stabilization in multiple Phase 2 studies WELL-TOLERATED with no preconditioning or immunosuppression required PHASE 3 STUDY is ongoing with pivotal topline re
Slide 5: ProKidney: Transforming CKD Care with Innovation and Execution
ProKidney Transforming Chronic Kidney Disease (CKD) Care with Innovation and Execution Building a future where advanced CKD treatment means more options and more hope First-in-class autologous cell therapy (RMAT designation) Rilparencel Robust Clinical Data Established Manufacturing Key Value Driver
Slide 6: 2025 Was a Pivotal Year at ProKidney
ProKidney 2025 Was a Pivotal Year at ProKidney Aligned with FDA on an accelerated approval pathway for rilparencel using eGFR slope as the surrogate endpoint in the Phase 3 PROACT 1 study Presented positive Phase 2 REGEN-007 data as a late-breaking clinical trial at American Society of Nephrology (A
Slide 7: Well Positioned to Deliver on Milestones in 2026 and Beyond
Complete enrollment for Phase 3 PROACT 1 accelerated approval efficacy analysis (n=~320) Mid-2026 Potential BLA submission of rilparencel Early 2028 Present results from ongoing mechanism of action studies at medical and scientific conferences Throughout FY 2026 Phase 3 PROACT 1 readout of confirmat
Slide 8: Chronic Kidney Disease: Significant Unmet Need and Limitations with Standard-of-Care
CHRONIC KIDNEY DISEASE Significant Unmet Need and Limitations with Standard-of-Care
Slide 9: CKD categories and risk of kidney failure
Persistent albuminuria categories Description and range A1 A2 A3 <30 mg/g <3 mg/mmol 30–300 mg/g 3–30 mg/ mmol >300 mg/g >30 mg/ mmol Normal to mildly increased Moderately increased Severely increased GFR categories (mL/min/1.73m2) Description and range G1 ≥90 Normal or high G2 60–89 Mildly decrease
Slide 10: Limited Therapeutic Options that Delay Dialysis in Stage 4 CKD
Limited Therapeutic Options that Delay Dialysis in Patients with Stage 4 CKD All recent landmark clinical trials in CKD primarily focus on Stage 2 and 3 CKD Study Active Product Subjects with Stage 4 CKD Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy1 Canagliflozin (SGLT2 inhibi
Slide 11: Standard of Care Has Limitations
Dapagliflozin: 19 patients required treatment to prevent one primary outcome event While New Therapies Are a Step Forward, Patients Still Lose Kidney Function and Experience Clinically Significant Events Standard of care includes ACE inhibitors, angiotensin receptor blockers and SGLT2 inhibitors Hee
Slide 12: Rilparencel Renal Autologous Cell Therapy
RILPARENCEL RENAL AUTOLOGOUS CELL THERAPY Transforming the Chronic Kidney Disease Treatment Landscape
Slide 13: Rilparencel: A Patient's Own Cells, From Biopsy to Kidney Therapy
Rilparencel: A Patient’s Own Cells—From Biopsy to Kidney Therapy NOT ALL CELL THERAPIES ARE CREATED EQUAL Rilparencel: Made from a patient’s own kidney cells No genetic modification No preconditioning No lifelong immunosuppression Well-tolerated with favorable safety profile Then frozen for preserva
Slide 14: Continued Expansion of In-House Manufacturing Facilities
Purchased two adjacent buildings in Winston-Salem, NC in November 2024, totaling approximately 180,000 square feet Currently supports Phase 3 PROACT 1 clinical manufacturing, with capacity to accommodate future commercial supply Ongoing capital investment in manufacturing infrastructure and systems
Slide 15: Advancing Kidney Care: Rilparencel Trials at a Glance
PRECLINICAL IND PHASE 1 PHASE 2 PHASE 3 STATUS Pivotal Trial Program Diabetes Type II – Prevent/Delay ESKD in Stage 3b/4 CKD (20-35 mL/min/1.73m2, n=~470) Ongoing Long term follow-up study for patients previously treated with rilparencel Ongoing Supportive Trials Diabetes Type II – Prevent/Delay ESK
Slide 16: REGEN-006 (PROACT 1) Rilparencel Registrational Program
Day –60 to Day 0 Screening Visit Sham Cohort Sham 1st Rilparencel Injection Sham 2nd Rilparencel Injection Sham Biopsy End of Study (EOS) 1st Rilparencel Injection 2nd Rilparencel Injection Biopsy End of Study (EOS) REGEN-006 (PROACT 1) Rilparencel Registrational Program Topline results for the eGFR
Slide 17: Increased Investment in R&D to Improve Understanding of Rilparencel MOA
In vitro Ex vivo In vivo (rodent) In vivo (human decedent) Kidney biopsy explant culture Primary kidney cells Kidney-on-chip Rodent models of CKD Rilparencel Control CKD donor Increased Investment in R&D to Improve Understanding of Rilparencel MOA MOA = Mechanism of Action Anticipated Results Quick:
Slide 18: Rilparencel Clinical Results
RILPARENCEL CLINICAL RESULTS Advancing Cell Therapy For Chronic Kidney Disease
Slide 19: Clinical Progression: From Proof to Pivotal Phase
2024 Clinical Progression: From Proof to Pivotal Phase 2 RMCL-002: Full results presented at ERA Stockholm 2024 SIGNAL Potential to preserve kidney function for 18 months; benefit to kidney function was most notable in subjects who had the highest risk of kidney failure SAFETY Comparable to kidney b
Slide 20: REGEN-007 Trial Design
REGEN-007 Trial Design Group 1 Dosing Regimen and Use of Cryopreserved Product Mirrors Phase 3 Program Type 1 or type 2 diabetes and CKD Subjects 30-80 years of age eGFR ≥20 and ≤50 mL/min/1.73m2 UACR 30-5000 mg/g HbA1c <10% Key Entry Criteria Day –60 to Day –7 Screening Visit u = Follow-up Visit Af
Slide 21: REGEN-007 Objectives and Endpoints
REGEN-007 Objectives and Endpoints Study Objective Evaluate the efficacy, safety, and durability of up to two rilparencel injections on progression of kidney disease in two patient groups using different dosing regimens Primary Efficacy Endpoint Difference in annual eGFR slope in the pre-injection p
Slide 22: REGEN-007 Baseline Characteristics
REGEN-007 Baseline Characteristics REGEN-007 (n=49) Group 1 (n=24) Group 2 (n=25) Age, years (mean +/- SD) 62 +/- 11 58 +/- 11 Female : Male, % 33% : 67% 28% : 72% Hispanic or Latino, % 0% 4% Race, % Black or African American 8% 16% White 92% 84% Other 0% 0% Type 1 Diabetes : Type 2 Diabetes, % 13%
Slide 23: Kidney Function Stabilized in Both Groups After Treatment
REGEN-007 Kidney Function Stabilized in Both Groups After Treatment with Rilparencel Annual decline in eGFR slope1 improved by 78% from -5.84 in the pre-injection period to -1.27 in the period following the last rilparencel injection. This 4.57 (1.95, 7.18)* mL/min/1.73m2 per year difference was sta
Slide 24: Kidney Function Stabilizes for Months After Treatment
REGEN-007 Kidney Function Stabilizes for 18 Months After Treatment with Rilparencel 15 10 5 0 -5 -10 -2 -1 0 1 2 Time (years) eGFR Change from Baseline (mL/min/1.73m2) Group 1 (n=24) Group 2 (n=25) 15 10 5 0 -5 -10 -2 -1 0 1 2 Time (years) eGFR Change from Baseline (mL/min/a1.73m2) Pre First-Injecti
Slide 25: REGEN-007 Individual Patient Slope Differences
Group 1 (n=24) Group 2 (n=25) Slope Difference (95% CI) No. of Participants (%) 2.6 (-1.2, 6.4) 3 (13) 4.9 (2.0, 7.9) 21 (88) Not evaluable 0 Not evaluable 2 (8) 3.6 (0.5, 6.6) 9 (38) 5.6 (1.5, 9.8) 13 (54) Not evaluable 0 5.2 (1.4, 8.9) 3 (13) 9.5 (3.2, 15.8) 7 (29) 0.2 (-2.3, 2.8) 14 (58) 6.7 (1.9
Slide 26: REGEN-007 Group 1 SGLT2i Use Summary
REGEN-007 Group 1 | SGLT2i Use Summary Ten patients (42%) were on SGLT2i at baseline; 3 of these 10 patients discontinued SGLT2i after receiving rilparencel An additional 8 patients (33%) initiated SGLT2i after receiving rilparencel In total, 18 patients (75%) received SGLT2i at some point during th
Slide 27: Baseline Characteristics: Patients Meeting Key PROACT 1 Criteria
REGEN-007 Baseline Characteristics: Patients Meeting Key Phase 3 PROACT 1 Inclusion Criteria HbA1c = hemoglobin A1c; ACE = angiotensin converting enzyme; ARB = angiotensin II receptor blockers; SGLT2i = sodium-glucose cotransporter-2 protein inhibitor; GLP-1 RA = glucagon-like peptide-1 receptor ago
Slide 28: Similar Efficacy Results in Patients Meeting PROACT 1 Criteria
REGEN-007 Similar Efficacy Results Were Observed in Patients Meeting Key Phase 3 PROACT 1 Inclusion Criteria 1. Annual eGFR slope calculated in mL/min/1.73m2 using a linear mixed effects model *(95% CI) Annual decline in eGFR slope1 improved by 85% from -6.46 in the pre-injection period to -0.95 in
Slide 29: No Rilparencel-Related Serious Adverse Events Were Observed
Adverse Event Biopsy # of SAEs (n=51) Rilparencel Injection # of SAEs (n=49) Rilparencel # of SAEs (n=49) Acute Kidney Injury 2 - - Death - - - Hematoma 2 1 - Hematuria 1 - - Hydronephrosis 1 - - REGEN-007 No Rilparencel-Related Serious Adverse Events Were Observed
Slide 30: Next Steps: Clinical Confidence, Strategic Path Forward
Next Steps FOCUS on the continued enrollment of patients in our registrational Phase 3 PROACT 1 study COMPLETE mechanism of action studies PREPARE for BLA submission and commercial launch Key Findings Bilateral dosing of cryopreserved product (which mirrors the Phase 3 study dosing regimen) resulted
Slide 31: Executing with Strength: Financial Snapshot
EXECUTING WITH STRENGTH Financial Snapshot
Slide 32: Strong Balance Sheet, Clear Path to Value Creation
MILESTONES KEY FINANCIALS Strong Balance Sheet, Clear Path to Value Creation Shares Outstanding 302,059,626* Cash Position $225M** Runway Expected to fund operations into mid-2027 Analyst Coverage 8 Firms Mid-2026 2026-2027 Q2 2027 Complete enrollment for accelerated approval efficacy analysis (n=32
Slide 33: Patients Want More Time
Patients Want More Time We are building a future where advanced CKD treatment means more options and more hope